OneBiomed closes $5m Series A led by BioPath, ARCH Venture Partners

One BioMed, a Singapore-based medical diagnostics company, on Wednesday announced that it has closed a $5 million Series A financing round led by Singapore-based Biopath Ventures and US-based ARCH Venture Partners.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.